C07K 2319/55
Containing a fusion with a toxin
Official title: containing a fusion with a toxin, e.g. diphteria toxin
C07K2319/55 (Containing a fusion with a toxin) appears on 906 US grants and 1,221 published applications in this corpus.
Search patents in C07K- Granted patents
- 906
- Published applications
- 1,221
- Assignees
- 586
- Inventors
- 1,979
- Latest grant
- 7 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 1 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 3 | 0 |
| 1988 | 0 | 0 |
| 1989 | 1 | 0 |
| 1990 | 4 | 0 |
| 1991 | 4 | 0 |
| 1992 | 13 | 0 |
| 1993 | 6 | 0 |
| 1994 | 8 | 0 |
| 1995 | 7 | 0 |
| 1996 | 16 | 0 |
| 1997 | 20 | 0 |
| 1998 | 22 | 0 |
| 1999 | 20 | 0 |
| 2000 | 18 | 0 |
| 2001 | 9 | 1 |
| 2002 | 8 | 13 |
| 2003 | 7 | 16 |
| 2004 | 8 | 16 |
| 2005 | 4 | 14 |
| 2006 | 10 | 23 |
| 2007 | 14 | 35 |
| 2008 | 9 | 31 |
| 2009 | 21 | 43 |
| 2010 | 17 | 40 |
| 2011 | 14 | 40 |
| 2012 | 22 | 30 |
| 2013 | 33 | 35 |
| 2014 | 28 | 47 |
| 2015 | 37 | 65 |
| 2016 | 38 | 99 |
| 2017 | 50 | 79 |
| 2018 | 62 | 69 |
| 2019 | 52 | 71 |
| 2020 | 71 | 88 |
| 2021 | 58 | 79 |
| 2022 | 60 | 80 |
| 2023 | 40 | 74 |
| 2024 | 40 | 56 |
| 2025 | 32 | 39 |
| 2026 | 17 | 38 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Engineered T cell receptors and methods of use7 Jul 2026US 12,673,980 B2Board of Regents, The University of Texas System
- Proteolytically stable U1-agatoxin-Ta1b variant polypeptides for pest control9 Jun 2026US 12,648,572 B2Vestaron Corporation
- Chimeric protein toxins for expression by therapeutic bacteria2 Jun 2026US 12,642,873 B1
- De-immunized Shiga toxin a subunit effector polypeptides for applications in mammals26 May 2026US 12,637,495 B2Molecular Templates, Inc.
- Consensus sequence of the antigen telomerase and the use thereof in preventive and therapeutic vaccination12 May 2026US 12,622,955 B2EvviVax S.r.l.
- Methods and compositions for treating cancer1 Oct 2026US 2026/0297152 A1
- Monobodies selective to nras10 Sep 2026US 2026/0263609 A1New York University
- Modified virus-like particles of cmv10 Sep 2026US 2026/0263612 A1Saiba GmbH
- Target protein expression platform using viral nucleocapsid10 Sep 2026US 2026/0265307 A1University-Industry Foundation, Yonsei University
- Nanostructured proteins and uses thereof10 Sep 2026US 2026/0265317 A1
Most cited
By later US patents
- Humanized antibodies and methods for making them1,003US 6,054,297 AGenentech, Inc. · 2000
- Covalently linked polypeptide cell modulators269US 4,935,233 AG. D. Searle & Co. · 1990
- Compositions for targeting the vasculature of solid tumors254US 6,051,230 ABoard of Regents, The University of Texas System · 2000
- Covalently-linked complexes and methods for enhanced cytotoxicity and imaging241US 5,169,933 ANeoRx Corporation · 1992
- CD4 adheson variants230US 5,336,603 AGenentech, Inc. · 1994